Cadila Healthcare Limiteda leading Indian Pharmaceutical company is a fully integrated, global healthcare providerheadquartered in Ahmedabad, Gujarat.
Cadila Healthcare Limitedis a Large Cap company with a market capital of Rs 33138.55 Crore.
Cadilamanufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products.The group is the market leader in the high-growth lifestyle segments such as gastrointestinal, cardiology, respiratory and gynaecology, which account for about 40% of its domestic formulation sales.
Cadila was founded in 1952 by Mr. Ramanbhai Patel and his business partner Mr. Indravadan Modi.
In 1995, the group was restructured, the founders, the Patel and Modi families split (the Modi family’s share was moved into a new company called Cadila Pharmaceuticals Ltd) andPatel family’s holding companyCadila Healthcare Limitedwas formed under the aegis of the Zydus group. As on September 30, 2019, the promoters held 74.88% stake in Cadila Healthcare, 4.49% held by foreign portfolio investors and the balance was held by the public and others.
Over the years, the Cadila Healthcarehas grown to become one of the top five pharmaceutical companies in India.
Zydus groupalso has growing presence in the regulated markets, particularly the US and is one of the top 10 players in the US generic market.
On 2007, the company acquired Química e FarmacêuticaNikkho do BrasilLtda (Nikkho) as part of Zydus Healthcare Brasil Ltda.
In 2015 the company acquired another Indian pharmaceutical company called German Remedies.
In 2018, Zydus groupannounced acquisition of Heinz India’s business comprising Complan, Glucon D, Nycil and Sampriti Ghee brands along with its two large manufacturing facilities for Rs. 4595 crores.
Zydus Cadila’s major shareholder remains the Patel family. Pankaj Patel (born 1951), son of the founder, is Chairman of the company.
From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 12,700 crores in FY19.
By the end of 31-03-2020, the company has a total of 1,023,742,600 shares outstanding.
The government has roped in Zydus Cadila for mass production of the country’s first indigenous ELISA test kit for antibody detection of covid-19 which was developed by National Institute of Virology in Pune.
If you find any mistake please contact the email@example.com. This article is general in nature. It does not constitute a recommendation to buy and sell any stock, and does not take account of your objectives, or your financial situation. Largecapindia has no position in the stocks mentioned.
Largecapindia aim to bring you long term focused research analysis driven by fundamental thanks you.
For More Info : https://www.largecapindia.com